Analysts forecast that Prothena Co. PLC (NASDAQ:PRTA) will announce sales of $260,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Prothena’s earnings, with the highest sales estimate coming in at $300,000.00 and the lowest estimate coming in at $230,000.00. Prothena posted sales of $220,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 18.2%. The firm is expected to issue its next earnings report on Tuesday, November 6th.
On average, analysts expect that Prothena will report full year sales of $1.03 million for the current financial year, with estimates ranging from $960,000.00 to $1.10 million. For the next financial year, analysts expect that the firm will report sales of $26.00 million per share, with estimates ranging from $900,000.00 to $51.10 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Prothena.
Prothena (NASDAQ:PRTA) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The firm had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.22 million. Prothena had a negative return on equity of 46.42% and a negative net margin of 21,884.38%.
A number of brokerages recently commented on PRTA. Barclays downgraded Prothena from an “equal weight” rating to an “underweight” rating and set a $12.00 price target for the company. in a report on Monday, May 21st. BidaskClub raised Prothena from a “hold” rating to a “buy” rating in a report on Wednesday, August 15th. Oppenheimer reissued a “hold” rating on shares of Prothena in a report on Friday, May 25th. Cantor Fitzgerald reissued a “buy” rating and issued a $18.00 price target (up previously from $14.00) on shares of Prothena in a report on Friday, June 15th. Finally, Zacks Investment Research downgraded Prothena from a “buy” rating to a “hold” rating in a report on Tuesday, May 22nd. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $45.91.
A number of hedge funds and other institutional investors have recently made changes to their positions in PRTA. Millennium Management LLC acquired a new stake in Prothena during the fourth quarter valued at approximately $338,000. Aperio Group LLC acquired a new stake in Prothena during the first quarter valued at approximately $222,000. Thrivent Financial for Lutherans raised its stake in Prothena by 127.9% during the first quarter. Thrivent Financial for Lutherans now owns 97,161 shares of the biotechnology company’s stock valued at $3,567,000 after buying an additional 54,521 shares in the last quarter. Employees Retirement System of Texas raised its stake in Prothena by 24.2% during the first quarter. Employees Retirement System of Texas now owns 113,000 shares of the biotechnology company’s stock valued at $4,148,000 after buying an additional 22,000 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Prothena by 45.0% during the first quarter. Russell Investments Group Ltd. now owns 32,064 shares of the biotechnology company’s stock valued at $1,177,000 after buying an additional 9,955 shares in the last quarter.
PRTA traded down $0.41 on Friday, reaching $13.39. The company’s stock had a trading volume of 379,133 shares, compared to its average volume of 256,301. Prothena has a 1 year low of $10.43 and a 1 year high of $70.00.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.
Read More: Stop Order Uses For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.